Loading
CRISPR and Genetic Engineering / Cancer Research and Treatments · Journal article
Artefactum · August 20, 2026
Raises a question worth testing. It does not answer one.
This is a narrative literature review examining CRISPR-Cas9-mediated BIRC5 knockdown as a potential strategy in triple-negative breast cancer. The review identifies promising preclinical signals—reduced tumor cell viability and enhanced sensitivity to conventional therapy—but concludes that clinical translation remains blocked by unresolved off-target effects, delivery system efficiency, and lack of in-vivo or clinical evidence.
Descriptive and analytical literature review. Published scientific literature on CRISPR-Cas9 gene editing, survivin (BIRC5), and triple-negative breast cancer; no direct human or animal subjects enrolled.. Intervention: CRISPR-Cas9-mediated BIRC5 gene editing (reviewed across literature).
CRISPR-Cas9-mediated gene editing reduces tumor cell viability in TNBC models CRISPR-Cas9 enhances sensitivity of neoplastic cells to conventional therapies Off-target effects and delivery system efficiency are identified as major technical barriers to clinical application
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize CRISPR-Cas9 targeting BIRC5 as a preclinical concept with no established role in TNBC treatment. Current practice remains unchanged; this approach is not ready for clinical testing without substantial improvements in delivery and specificity.
A literature review synthesizing preclinical and mechanistic evidence on CRISPR-Cas9 for BIRC5 modulation in TNBC; raises therapeutic potential but acknowledges unresolved technical barriers and lack of clinical translation.
As stated by the source record.
Clinicians should recognize CRISPR-Cas9 targeting BIRC5 as a preclinical concept with no established role in TNBC treatment. Current practice remains unchanged; this approach is not ready for clinical testing without substantial improvements in delivery and specificity.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is characterized by the absence of hormone receptor and HER2 expression, constituting a subtype with high biological aggressiveness and limited therapeutic options. In this context, the BIRC5 gene stands out for encoding the survivin protein, whose overexpression is directly associated with apoptosis inhibition, tumor progression, and resistance to conventional treatments. From this perspective, the present study aimed to analyze the potential of the CRISPR-Cas9 system as a therapeutic tool in TNBC, with emphasis on BIRC5 modulation. This is a descriptive and analytical literature review based on scientific articles published between 2014 and 2025, retrieved from the PubMed, Scopus, and Google Scholar databases. The literature analysis demonstrates that CRISPR-Cas9-mediated gene editing has a significant impact on reducing tumor cell viability, in addition to enhancing the sensitivity of neoplastic cells to conventional therapies. However, the clinical applicability of this approach is still limited by relevant technical challenges, particularly those related to off-target effects and the efficiency of delivery systems. Therefore, although CRISPR-Cas9 has emerged as a promising strategy in the context of precision oncology, its incorporation into clinical practice depends on improvements in safety, specificity, and therapeutic feasibility, as well as on integration with complementary approaches.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.